Dr. Louis M. Aledort is a board-certified internist and hematologist who began his Mount Sinai career in 1966. A former Dean for Faculty and Hospital Affairs at Mount Sinai School of Medicine, Dr. Aledort has been The Mary Weinfeld Professor of Clinical Research in Hemophilia since 1993.
Dr. Aledort earned his medical degree at the Albert Einstein College of Medicine of Yeshiva University as a member of its first graduating class, in 1959. He continued his studies as a resident at the University of Virginia and at Strong Memorial Hospital in Rochester, NY, where he also had a Hematology Fellowship. From Rochester, Dr. Aledort joined Mount Sinai, where he has remained for 45 years.
A pioneer in the study and treatment of coagulation disorders, Dr. Aledort continues to be the one of the world’s leading authorities on hemophilia. He has long been at the forefront of developing comprehensive care for hemophilia, including creating The Mount Sinai Regional Comprehensive Hemophilia Treatment Center, which has been designated as a World Health Organization Global Cooperating Training Center in Coagulation Diseases. He has been involved in this field for over 50 years, through his academic research and community and service efforts.
Dr. Aledort has been a leader in the design and implementation of several groundbreaking collaborative study groups, including the U.S. Hemophilia Study Group, the Transfusion Safety Study, and the Orthopedic Outcome Study. He has authored more than 400 peer-reviewed articles in prominent journals, including Haemophilia, Journal of Thrombosis and Haemostasis, and the American Journal of Hematology
Dr. Aledor's research interests include:
- White cell disorders
- Red cell disorders
- Platelet disorders
Potency of Human Interferon Î²â1a and Human Interferon Î²â1b in Enzymotherapy, Immunotherapy, Chemotherapy, Radiotherapy, Hormone Therapy and Targeted Therapy of Encephalomyelitis Disseminate/Multiple Sclerosis (MS) and Hepatitis A, B, C, D, E, F and G VirusEditorial: J Proteomics Enzymol 2017, 6:1
- Research Article: J Proteomics Enzymol 2016, 5:1
Biliaminu SA, Abdul Azeez, Abdur Rahman MB and Ajani S
Will PD-1/PD-L1 Inhibitor Become a True Salvage Therapy for Relapsed or Refractory Patients with Hematological Malignancies?Editorial: J Clin Exp Oncol 2017, 6:3
The Effect of Current Limiting Reactors to Shut off Short Circuits in Electrical High Voltage NetworksResearch Article: J Electr Eng Electron Technol 2016, 5:3
Volkov MS, Gusev YP, Monakov YV and Cho GC